Dosage Modification for Adverse Reactions

If an adverse reaction (AR) listed below occurs, interrupt IMBRUVICA® therapy at each occurrence of the same AR. Once the AR has improved to grade 1 or baseline, follow the recommended dosage modifications below.1

See full Prescribing Information for Warnings and Precautions.

Grading based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria, or International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for hematological toxicities in CLL/SLL.

Evaluate the benefit-risk before resuming treatment.

§For Grade 4 non-hematological toxicities, evaluate the benefit-risk before resuming treatment.

For use with CYP3A inhibitors and inducers, and in patients with hepatic impairment, please see the full Prescribing Information. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding. Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.

WM=Waldenström's Macroglobulinemia.​​

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.